Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.